Blog
Protein Indication Switching: Challenges Costs and Solutions!
β οΈ Switching indications for established protein molecules can present challenges in manufacturing and patent protection. ππππ‘
UK Biotech Company Receives Grant to Revolutionize Cell and Gene Therapy
π’ Exciting News! MicrofluidX receives UK grant to enhance its cell and gene therapy platform for improved scalability, cost-effectiveness, and efficiency. ππ§¬π
Cutting-Edge Bioanalytics Revolutionize AAV Research and Manufacturing
π Dec 12, 2023: Explore the crucial innovations in bioanalytics for AAVs, from R&D to manufacturing. π‘π§ͺπ
Revolutionary Method Boosts AAV Capsid Purification!
π Dec 12, 2023: Study reveals high-resolution chromatography method to boost AAV capsid purification. π𧬠Improved gene therapy potential!
Slash Healthcare Costs with Game-Changing Biosimilars
π Discover how biosimilars can reduce healthcare costs by delivering the same efficacy at a lower price. ππ°π₯π§¬π¬
Cytomos Revolutionizes Advanced Therapy Manufacturing with Cell Characterization Tech
π’ Cytomos is revolutionizing advanced therapy manufacturing with their unique technology to monitor and detect potential batch failures. π‘
Major Milestone: Charles River & Vertex Revolutionize Cell Therapy Manufacturing
π Dec 18, 2023: Charles River Laboratories achieves milestone in manufacturing CASGEVY, first FDA-approved CRISPR therapy for sickle cell disease. ππ¬
Unlocking Protein Product Opportunities: Overcoming Challenges with QTL Technology
π’ Recombinant proteins have the potential to transform industries, but technical challenges hinder their commercial scaling. π Inaccurate risk assessments prevent the exploration of protein product possibilities. π Scaling protein manufacture requires substantial investment and addressing technical complexity. π‘ Quantitative Trait Loci (QTL) technology enables tailored manufacturing solutions for individual products. β QTL technology can overcome technical challenges and unlock commercial opportunities for protein products.
Revolutionary Scandinavian Bioinks for Regenerative Medicine
π§ͺ Scandinavian scientists have developed bioinks for regenerative medicine that combine dynamic and nondynamic linkages. 𧫠These bioinks can be used for cellular interactions in 3D and in vivo implantation. π©Ή Three hydrogels were developed, with the DT-gel being the most promising for cartilage regeneration. π‘ The D-gel has potential for wound healing and cancer cell metastasis research. π¬ The T-gel supports cell proliferation and stability. π The hydrogels showed stability in a buffer environment and increased expressions of stemness markers. π± Future research aims to explore the chondrogenic properties of the hydrogels for cartilage regeneration and tissue model construction.
Uncovering the Tender Trap: How Biosimilar Policymaking Impacts Access to Affordable Medicines
π Manufacturing innovations may reshape biosimilar policymaking, leading to lower prices and increased accessibility. ππ
